The Impact of Vitamin D Supplementation on the IFNγ-IP10 Axis in Women with Hashimoto's Thyroiditis Treated with Levothyroxine: A Double-blind Randomized Placebo-controlled Trial

Iran J Allergy Asthma Immunol. 2022 Aug 12;21(4):407-417. doi: 10.18502/ijaai.v21i4.10288.

Abstract

Hashimoto's thyroiditis (HT) results from chemoattraction of inflammatory cells toward the thyroid gland by inducing the production of interferon-gamma (IFNγ)-induced protein 10 (IP10) by T helper (Th) 1 cells. Vitamin D may suppress the IFNγ-IP10 axis, but this new function of vitamin D has not yet been investigated in HT patients. In an intervention and control group, patients received 50000 IU cholecalciferol or placebo every week for three months, respectively. The CD4+ T cells of 40 patients were isolated, and the mRNA expression levels of vitamin D receptor (VDR), peroxisome proliferator-activated receptors (PPAR)-α, and PPAR-γ genes were determined by real-time PCR. ELISA method was used to determine serum levels of vitamin D, tumor necrosis factor-alpha (TNF-α), IFN-γ, and IP10. Vitamin D levels in the intervention group were significantly higher than in the placebo group after supplementation. PPAR-α and PPAR-γ gene expression levels did not differ significantly between the two groups. The serum levels of IP10, IFNγ, and TNF-α decreased significantly in the vitamin D group, as well as in the placebo group. During this study, vitamin D levels significantly increased in the intervention group and inflammatory factors decreased. Based on the similar results obtained in the placebo group, further studies with larger sample sizes and longer intervention times are recommended.

Keywords: CD4-positive T-lymphocytes; Hashimoto disease; Interferon-gamma; Peroxisome proliferator-activated receptors; Th1 cells; Vitamin D.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Chemokine CXCL10 / therapeutic use
  • Cholecalciferol / therapeutic use
  • Dietary Supplements
  • Double-Blind Method
  • Female
  • Hashimoto Disease* / drug therapy
  • Humans
  • Interferon-gamma
  • Peroxisome Proliferator-Activated Receptors / therapeutic use
  • RNA, Messenger
  • Receptors, Calcitriol / genetics
  • Receptors, Calcitriol / therapeutic use
  • Thyroxine* / therapeutic use
  • Tumor Necrosis Factor-alpha
  • Vitamin D / therapeutic use

Substances

  • Chemokine CXCL10
  • Peroxisome Proliferator-Activated Receptors
  • RNA, Messenger
  • Receptors, Calcitriol
  • Tumor Necrosis Factor-alpha
  • Vitamin D
  • Cholecalciferol
  • Interferon-gamma
  • Thyroxine